MedPath

Clinical study of Solifenacin and Imidafenacin in OAB patients with nocturia

Not Applicable
Conditions
Overactive bladder
Registration Number
JPRN-UMIN000009137
Lead Sponsor
Clinical Research Support Center Kyushu
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients who have administered prohibited substances or done prohibited therapy within the 4weeks before enrollment 2) Patients who started restricted substances and changed usage or dosage of restricted substances for determined period before enrollment 3) Patients with prostate cancer, neurogenic bladder, urethral stricture, chronic bacterial prostatitis, urinary tract infection, urinary tract stones and interstitial cystitis 4) Patients with urinary retention 5) Patients with obstruction of pylorus, duodenum and gut and patients with paralytic ileus 6) Patients with decrease of enterokinesis and gastrointestinal tract tension 7) Patients with closure-angle glaucoma 8) Patients with myasthenia gravis 9) Patients with serious liver dysfunction, kidney dysfunction and heart disease. 10) Hypersensitivity to anti-cholinergic agents. 11) Residual urine volume is more than 100mL 12) Patients with polyuria 13) Any other patients who are regarded as unsuitable for this study by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sefulness for nocturia
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath